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Lamivudine in hepatitis B–associated membranous nephropa-
thy.
Background. Although lamivudine is effective for treatment
of chronic hepatitis B (HBV) infection, its potential therapeu-
tic impact on HBV-related membranous nephropathy (MN) in
adults has not been characterized.
Methods. We treated 10 HBsAg-positive patients with
biopsy-proven MN, elevated serum alanine aminotransferase
(ALT), and HBV-DNAemia (group 1), and compared their clin-
ical course with 12 patients diagnosed to have HBV infection,
elevated serum ALT, and MN in the pre-lamivudine era (group
2).
Results. Baseline demographic and clinical parameters were
not different between the 2 groups. In group 1, lamivudine treat-
ment was associated with significant reduction in proteinuria,
increase in serum albumin, normalization of ALT levels, and
disappearance of circulating HBV-DNA during the first year.
Four (40%) and 6 (60%) patients went into complete remis-
sion (proteinuria <0.3 g/d) at 6 and 12 months, respectively. In
group 2, significant proteinuria persisted during the first year.
One (8.3%) and 3 (25%) patients went into remission. Cumula-
tive 3-year renal survival [using end-stage renal disease (ESRD)
as primary end point] was 100% in group 1 and 58% in group 2
(P = 0.024, log rank test). Blood pressure control reached the
target of below 130/85 mm Hg in both groups. Lamivudine was
well tolerated and not associated with any adverse events. Hep-
atic decompensation or malignancy was not observed during
follow-up in both groups.
Conclusion. HBV-related MN leads to ESRD in a significant
proportion of patients before the advent of antiviral therapy.
Lamivudine treatment improves renal outcome in HBV carriers
with MN and evidence of liver disease.
Membranous nephropathy (MN) is the most common
cause of adult nephrotic syndromes worldwide. Its as-
sociation with hepatitis B virus (HBV) infection was first
described by Combes et al in 1971 [1]. To date, HBV infec-
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tion remains an important cause of MN in endemic areas.
While steroids and alkylating agents are the mainstay of
treatment for idiopathic forms of MN in Caucasian and
Chinese patients [2, 3], there is little consensus on the op-
timal choice of drug for the treatment of HBV-associated
MN. Steroids and cytotoxic agents may cause more harm
than good by enhancing viral replication and precipitat-
ing hepatitic flares [4]. Interferon-alpha, while reported
to be useful in children [5, 6], has produced mixed results
in adults with HBV-associated MN [7, 8].
The introduction of the nucleoside analog, lamivu-
dine, has revolutionized the treatment of chronic HBV
infection [9, 10]. Lamivudine is the (-)-enantiomer of
3′-thiacytidine, and it inhibits DNA synthesis by terminat-
ing the nascent proviral DNA chain through interference
with the reverse transcriptase activity of HBV. In children
with HBV-associated MN, lamivudine has been anecdo-
tally reported to induce remission of nephrotic syndrome
in 2 case reports [11, 12]. However, its efficacy in HBV-
associated MN with nephrotic syndrome in adults has not
been systematically studied. Here, we report the long-
term outcome in 10 patients with HBV-associated MN
who were treated with lamivudine. Their clinical course
was compared with 12 historic control subjects who pre-
sented in the pre-lamivudine era.
METHODS
Patient selection
Upon the availability of lamivudine in Hong Kong in
1998, all consecutive patients with HBV-associated mem-
branous nephropathy, hepatitis B surface antigen (HB-
sAg) positivity, urinary protein excretion rate exceeding
3 g/24 hours, elevated serum alanine aminotransferase
(ALT) levels (≥1.5 times the upper limit of the normal
range), serum creatinine less than 250 lmol/L, and circu-
lating HBV DNA detectable by Digene Hybrid Capture
II Assay (Digene Diagnostics, Inc., Beltsville, MD, USA)
[13] were enrolled to receive lamivudine 100 mg p.o. daily.
Other secondary causes of MN, namely neoplasms,
infections other than hepatitis B, connective tissue
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Table 1. Baseline demographic and clinical characteristics in subjects with HBV-associated MN who received (group 1, diagnosed from
1998–2001) or did not receive (group 2, diagnosed from 1988–1997) lamivudine treatmenta
Group 1 (N = 10) Group 2 (N = 12)
Age years 48.3 ± 12.8 43.1 ± 22.8
Gender M:F 7:3 7:5
Disease duration from diagnosis to start of antiviral therapy months 5.7 ± 4.4 N/A
Urine protein excretion g/day 4.9 ± 2.4 4.2 ± 0.9
Presence of microscopic hematuria (percentage of subjects) 90% 83%
Serum creatinine mg/dL b 0.98 ± 0.18 0.94 ± 0.18
Serum albumin g/dL c 2.6 ± 0.6 2.92 ± 0.65
Serum C3 mg/dL d 87.3 ± 47.6 98.8 ± 27.3
Serum C4 mg/dL d 15.2 ± 8.9 15.6 ± 13
Serum ALT (times upper limit of normal)e 2.2 ± 1.2 2.4 ± 1.4
HBsAg-positive (percentage of subjects) 100% 100%
HBeAg-positive (percentage of subjects) 70% 67%
HBV DNA-positive (percentage of subjects) 100% U/A
Serum HBV DNA pg/mL f 475.3 ± 266.1 U/A
Stage of glomerular lesiong (percentage of subjects)
I or II 70% 75%
III or IV 30% 25%
Presence of mesangial glomerular sclerosis (percentage of subjects) 20% 17%
Presence of tubulointerstitial lesions (percentage of subjects) 30% 25%
Hypertension (percentage of subjects) 33% 25%
Received lamivudine (percentage of subjects) 100% 0%
Received ACEi or ARB (percentage of subjects) 100% 100%
Abbreviations are: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ALT, alanine aminotransferase; HBsAg, hepatitis B
surface antigen; HBeAg, hepatitis B e antigen; N/A, not applicable; U/A, unavailable.
a Plus-minus values are mean ± SD. P > 0.05 for all comparisons between the two groups, except for characteristics that are not comparable because data in group 2
were unavailable.
b The normal range for serum creatinine is 0.93 to 1.43 mg/dL. To convert values to micromoles/L, multiply by 88.4.
c The normal range for serum albumin is 4.2 to 5.4 g/dL.
d The normal ranges for serum C3 and C4 are 76 to 150 mg/dL and 9 to 35 mg/dL, respectively.
e The upper limit of the normal range for ALT is 41 IU/L.
f By Digene Hybrid Capture II Assay (Digene Diagnostics, Inc., Beltsville, MD, USA) with a detection threshold of 0.5 pg/mL [13].
g Determined in accordance with the staging by Ehrenreich et al [15].
disorders, or putative drugs and toxins, were actively ex-
cluded. The study was approved by the local Institution
Review Board and Hospital Ethics Committee. Patients
with other forms of renal pathologies, including membra-
noproliferative glomerulonephritis, were excluded from
the analysis.
All patients who presented in the pre-lamivudine era
from 1988 leading up to 1997 with histologically proven
membranous nephropathy, HBsAg positivity, urinary
protein excretion rate exceeding 3 g/24 hours, elevated
serum ALT levels (≥1.5 times the upper limit of the nor-
mal range), serum creatinine less than 250 lmol/L, and
comparable histologic score, were included in the anal-
ysis as historic controls. Patients with previous exposure
to interferon therapy were excluded.
Patients in both cohorts were treated with an
angiotensin-converting enzyme inhibitor (ACEi) with or
without additional antihypertensive agents to achieve
a blood pressure target of below 130/85 mm Hg. An-
giotensin II receptor blockers (ARB) only became read-
ily available in Hong Kong from 1999, and patients who
could not tolerate ACEi-related side effects (most com-
monly intractable cough) were given an ARB. Complete
remission of proteinuria was defined as a value for uri-
nary protein excretion that was below 0.3 g/24 hours; par-
tial remission was defined as a decline in urinary protein
excretion by 50% or more over baseline value but the
absolute amount of proteinuria was over 0.3 g/24 hours.
Treatment failure was defined as persistence of urinary
protein excretion that exceeded 50% of the baseline
value.
Histologic diagnosis of HBV-associated MN
The histologic diagnosis of HBV-associated MN was
based on studies with light, immunofluorescence, and
electron microscopies. Renal tissue samples were rou-
tinely processed and stained with hematoxylin-eosin, pe-
riodic acid–Schiff, Masson’s trichrome, Jones’s silver, and
Congo red stains. For direct immunofluorescence, frozen
sections of the fresh tissue samples were stained with an-
tisera against human C3, C4, C1q, IgA, IgM, IgG, and
fibrinogen. Demonstration of HBV-specific antigens was
performed by indirect immunofluorescence using a rab-
bit polyclonal antibody against HBcAg (1:50 dilution;
Dakopatts, Copenhagen, Denmark) according to meth-
ods described previously [14]. The polyclonal antibody
exhibits both anti-HBc and anti-HBe activities [14]. In ad-
dition, ultrastructural examination for viral-like inclusion
particles was performed by an experienced histopatholo-
gist specialized in this area. Histologic grading of MN was
determined by 2 renal pathologists, without knowledge of
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Fig. 1. Characteristic features of HBV-associated membranous nephropathy. (A) Representative electron micrograph of MN from one of the
subjects in group 1, showing the typical presence of both subepithelial (more numerous) and subendothelial electron-dense deposits (×13,000).
(B) Positive granular staining along the glomerular capillary wall in immunofluorescence study with polyclonal anti-HBc (×300). (C) Viral-like
particles (arrows) appearing as clusters of round to ovoid structures of 10 to 30 nm in diameter and varying density distributed with the glomerular
capillary basement membrane electron-dense deposits (×30,000).
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Fig. 2. Blood pressure control during follow-up.
patients’ clinical status, in accordance with the staging by
Ehrenreich et al [15].
Statistics
All data are presented as mean ± SD unless otherwise
specified. Continuous variables at the start of treatment
were compared with Wilcoxon rank-sum tests. Categor-
ical groups were compared by the chi-square test and
Fisher exact test, as appropriate. The primary outcome
measure was the development of end-stage renal disease
(ESRD) that necessitated renal replacement therapy. In-
tragroup differences in continuous data were compared
with the Wilcoxon signed rank test, while intergroup dif-
ferences were compared with the Mann-Whitney U test.
The cumulative percentage of patients who went into re-
nal failure requiring replacement therapy was calculated
with the Kaplan-Meier method, and comparisons be-
tween groups were made with the log-rank test. Change
in serum creatinine levels over time between the 2 groups
was compared using multivariate analysis of variance
(ANOVA) for repeated measures with adjustment for
baseline variations. Multiple linear regression analyses
were used to explore whether histologic stage, type of
HBV antigen in renal tissue, or circulating HBV DNA
levels at baseline, or clearance of HBeAg, seroconver-
sion to anti-HBe, or ALT normalization during follow-up
may each predict renal response to lamivudine treatment
in group 1. A two-tailed P value of less than 0.05 was taken
as the level of significance.
RESULTS
From 1998 until June 2001, we have treated 10 HBsAg-
positive patients with nephrotic syndrome, biopsy-
proven MN, elevated serum alanine aminotransferase
(ALT), and evidence of HBV-DNAemia (group 1) with
lamivudine (100 mg p.o., Q.D.). Their baseline demo-
graphic and clinical data were compared with 12 historic
control subjects (group 2) who presented from 1988 to
1997 with nephrotic syndrome, MN, and concurrent HBV
infection in whom specific antiviral therapy was not given
because it was not yet available (Table 1). Renal biopsy
samples of all subjects fulfilled the histologic criteria for
diagnosis of HBV-associated MN. A representative elec-
tron micrograph is shown in Figure 1A. Renal tissues of
all patients in group 1 and 10 patients in group 2 demon-
strated positive staining with polyclonal anti-HBc along
the glomerular capillary wall (Fig. 1B). The remaining
2 subjects exhibited viral-like particles, which appeared
upon ultrastructural examination as clusters of round to
ovoid structures of 10 to 30 nm in diameter and varying
density distributed with the glomerular capillary base-
ment membrane electron-dense deposits (Fig. 1C), sim-
ilar in appearance to those reported previously [4]. All
patients in both groups achieved target blood pressure
control within 6 months of diagnosis, using either an ACEi
or ARB with or without additional antihypertensive
agents (Fig. 2). All patients had normal ultrasonographic
findings of the liver and prothrombin times, except
1 group 1 subject with sonographic features of cir-
rhosis. One patient in group 2 developed rheuma-
toid arthritis 15 years after initial presentation of
MN.
In group 1, the mean follow-up duration was 49.2 ±
16.5 months (range 36–75.4). There was significant
reduction of proteinuria from 6 months of starting
lamivudine treatment and beyond (Fig. 3). By 3 years,
the median urinary protein excretion was 0.19 g/24 hours.
Four (40%), 6 (60%), and 7 (70%) patients went into
complete remission (proteinuria < 0.3 g/24 h) after 6,
12, and 36 months of lamivudine treatment, respectively.
There was also concomitant increase in serum albumin
(3.34 ± 0.8, 3.63 ± 0.69, 4.07 ± 0.43 g/dL at 6, 12, 36
months, respectively; P = 0.021, 0.008, 0.005 vs. base-
line, respectively). ALT levels were normalized in 2,
6, and 8 patients at 6, 12, and 36 months, respectively
(Fig. 4). One patient developed rebound of ALT and sig-
nificant proteinuria 6 months after an attempt to discon-
tinue lamivudine at 2 years. Transaminasemia and HBV
DNAemia persisted in another patient in whom protein-
uria never remitted. Circulating HBV DNA fell below
detection threshold in the remaining 8 patients within the
first year (median 4 months) of treatment. Five patients
cleared HBeAg, 3 of whom seroconverted to anti-HBe
(Table 2). Lamivudine was well tolerated in all subjects
and not associated with any adverse events that required
dosage adjustment or drug discontinuation. Multiple lin-
ear regression analyses failed to identify a predictor of
renal response to lamivudine treatment over the study
period.
In group 2, significant proteinuria persisted at 6 months
(median 3.6 g/24 h) and 12 months (median 3.0 g/24 h) of
diagnosis (Fig. 3). One (8.3%) and 3 (25%) patients went
into complete remission at 6 and 12 months, respectively.
By 3 years of follow-up, 5 patients (42%) had developed
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ESRD: 2 received renal transplantation and 3 were es-
tablished on peritoneal dialysis. Those who progressed to
ESRD had higher mean baseline proteinuria (3.6 ± 0.32
g/24 hours in nonprogressors vs. 5.0 ± 0.87 g/24 hours in
progressors, P = 0.007). Other factors that may predict
progression to ESRD were not identified. The remaining
patients without ESRD, who were followed for a mean
of 181 ± 88 months, continued to have fluctuating levels
of ALT (Fig. 4) and proteinuria, although the intergroup
difference in ALT was not statistically significant. Three
patients lost HBeAg, 2 of whom developed anti-HBe
(Table 2).
The cumulative 3-year renal survival was 100% in
group 1 and 58% in group 2 (P = 0.024, log-rank test)
(Fig. 5). Change in serum creatinine over time was shown
in Figure 6. Treatment with lamivudine was associated
with a 41% reduction in the actual risk of progression to
ESRD within 3 years, and a protection odds ratio of 7.3
(95% CI 0.7–81). Hepatic decompensation or malignancy
was not observed during follow-up in both groups.
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Table 2. HBV e-serologies and clinical remission status in all subjects
At 12 months At 36 months
At Baseline
ALTb Renal ALTb Renal
Subject # HBeAg Anti-HBe HBeAg Anti-HBe normalized Outcome HBeAg Anti-HBe normalized Outcome
Group 1
1a + − − − yes PR − + no PR
2 − + − + no CR − + yes CR
3 + − − − yes PR − + yes CR
4 + − − − no NR − − no PR
5 + − − + no CR − + yes CR
6 + − + − no PR + − yes CR
7 − + − + yes CR − + yes CR
8 + − + − yes CR − − yes PR
9 − + − + yes CR − + yes CR
10 + − + − yes CR + − yes CR
Group 2
11 + − − + yes CR − + yes CR
12 + − − − no PR − + no PR
13 + − + − no NR + − no NR
14 − + − + no NR − + no NR
15 + − + − yes NR − − yes NR
16 − + − + no NR − + no ESRD
17 − + − + yes CR − + yes CR
18 + − + − no NR + − no ESRD
19 + − + − no NR + − no ESRD
20 + − + − no NR + − no ESRD
21 − − − − no ESRD − − no ESRD
22 + − + − no CR + − yes PR
Abbreviations are: CR, complete remission of proteinuria (<0.3 g/24 hrs); PR, partial remission of proteinuria (≥50% reduction from baseline, but exceeding 0.3
g/24 hrs); NR, no remission of proteinuria; ESRD, end-stage renal disease.
aLamivudine was stopped after 2 years’ treatment.
bAbsolute ALT level below upper limit of normal range.
DISCUSSION
Although the pathogenesis of HBV-related MN is not
fully understood, the detection of at least 1 of the 3 ma-
jor HBV antigens, namely HBsAg, HBeAg, and HBcAg,
in the glomerulus suggests a mechanism involving HBV-
related immune complexes formed by passive trapping or
in situ formation [16]. Spontaneous remission observed
in pediatric patients who showed simultaneous serocon-
version of HBeAg to anti-HBe provides an additional
evidence of an immune complex mechanism [17]. Fur-
thermore, HBsAg is characteristically localized in the
mesangium, while HBeAg is found in the glomerular cap-
illary loop [18]. These findings form the basis of employ-
ing agents targeted at virus eradication in the treatment
of HBV-associated MN.
Unlike childhood disease, in which there is a high
rate of spontaneous remission [19, 20], adults with HBV-
associated MN typically develop progressive disease [7].
Thus, there is a pressing need to develop an effective
form of treatment for the latter. However, experience
with antiviral treatment for HBV-associated MN in adults
has thus far been limited to trials with interferon, and
the results were disappointing in Chinese subjects [7].
Here, we show for the first time that lamivudine signif-
icantly improves the clinical outcome of HBV-related
MN. Such improvement was independent of blood pres-
sure control, which is an important confounder [21].
The dramatic suppression of viral proliferation follow-
ing lamivudine therapy, consistent with its established
clinical efficacy in chronic HBV carriers [10], together
with prompt remission of the nephrosis, provides further
support for a pathogenetic role of the hepatitis B virus
in this disease. Because of the small patient number, we
were unable to identify in the present study predictors
of treatment response to lamivudine, such as histologic
stage at baseline, or clearance of HBeAg, seroconver-
sion to anti-HBe, or ALT normalization during follow-up.
However, it is important to realize that although sero-
conversion to anti-HBe is commonly taken as a favor-
able prognostic factor among chronic HBV carriers in
the past, emerging data show that disease progression
can continue even after anti-HBe seroconversion, par-
ticularly in Asian and Mediterranean populations [22].
Thus, the clinical significance of anti-HBe seroconversion
in the setting of HBV-associated membranous nephropa-
thy remains to be addressed. Although patients who did
not receive lamivudine therapy before its availability also
displayed a moderate downward trend in urine protein
excretion over time, they typically had fluctuating lev-
els upon extended follow-up. The lack of difference in
proteinuria between the 2 groups at 36 months could be
explained by the fact that those with severe and unremit-
ting nephrosis in group 2 had developed ESRD at which
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Fig. 5. Kaplan-Meier analysis of renal survival in patients who received
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HBV-associated MN.
their clinical data were censored. The same is also true
for the apparent lack of difference in serum creatinine
values.
The rate of progression to ESRD in the historic con-
trol group is higher than that reported by others [18],
reflecting a poorer prognosis in this group. This may be
due to our selection of patients with heavy proteinuria
exceeding 3 g/24 hours in our analysis. Indeed, the obser-
vation among group 2 subjects that those who progressed
to ESRD had higher baseline levels of urine protein loss
supports the current concept that abnormal protein traf-
ficking within the kidney in diabetic and nondiabetic re-
nal diseases is detrimental to renal survival [23, 24]. In
vitro studies have shed light on the toxicity of protein-
uria, per se, on renal tubules and its role in the progres-
sion of renal failure [25–28]. Excessively filtered urinary
proteins induce renal tubular expression of proinflam-
matory and fibrogenic cytokines that act in concert to
orchestrate tubulointerstitial inflammation, fibrosis and,
ultimately, loss of renal function.
Although treatment with lamivudine is associated with
a 41% reduction in the actual risk of progression to ESRD
within 3 years, the odds ratio for renal protection did not
reach statistical significance. This is likely a result of small
patient numbers in both arms. An important barrier in
patient recruitment in the present study is the require-
ment of urinary protein excretion rate to exceed 3 g/24
hours. Future studies could focus on patients with milder
forms of proteinuria, for example, over 1 g/day. Another
weakness of the present study is its nonrandomized na-
ture. However, given the observed efficacies of antiviral
therapy in terms of proteinuria and ALT reduction and
renal survival in our patients, it may not be ethical or in
the best interest of patients afflicted with this condition
to receive placebo treatment. Such observation forms the
basis for our retrospective recruitment of control subjects
who presented in the pre-lamivudine era. We tried every
possible means to match the baseline characteristics and,
particularly, the use of blockers of the renin-angiotensin
axis, blood pressure control, and histologic grading be-
tween the 2 groups.
Overall, our results suggest that antiviral therapy with
lamivudine is indicated in patients with histologically
confirmed HBV-associated nephropathy, which includes
demonstration of HBV-specific antigens on the renal
biopsy, and even normal or only slightly elevated ALT
levels. The duration of lamivudine therapy remains an
unresolved issue. Our attempt to withdraw treatment af-
ter 2 years of complete remission in the first patient we
treated resulted in relapse of nephrosis. Thus, it is rea-
sonable to maintain patients on long-term lamivudine
treatment after initial remission. A potential limitation
of prolonged treatment with lamivudine is the emergence
of drug-resistant strains due to the induction and selec-
tion of HBV variants with mutations at the YMDD motif
of DNA polymerase [29], which has, thus far, not been
observed in our cohort. One agent that might be consid-
ered in case of lamivudine resistance is adefovir dipivoxil,
which is effective against both lamivudine-resistant HBV
mutants as well as wild-type HBV [30]. However, this
agent is potentially nephrotoxic and there are no clini-
cal data on its efficacy in HBV-related MN that does not
respond to lamivudine treatment.
CONCLUSION
HBV-related MN leads to ESRD in a significant pro-
portion of patients before the advent of specific antiviral
therapy. Lamivudine treatment improves renal outcome
in HBV carriers with MN and evidence of liver disease.
Randomized studies in a larger cohort of patients are
needed to validate this important issue.
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